Exozymes Inc. (EXOZ) intrinsic value & 10-year financials
Exozymes Inc. (EXOZ) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $4.09
- Market cap
- $34.3M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -408.2%
- Free cash flow (FY2025)
- -$6.7M
EXOZ 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$9.2M | -$1.09 | -$6.7M | — | -613.2% |
| FY2024 | — | -$5.9M | -$0.89 | -$8.9M | — | -419.5% |
| FY2023 | $70.1K | -$2.0M | -$0.33 | -$1.5M | -2563.5% | -191.9% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
EXOZYMES INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
EXOZYMES INC. has historically struggled to out-earn its cost of capital, averaging just -4.1% ROIC.
EXOZYMES INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
EXOZYMES INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.